SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Moriki, T. Articles by Ikeda, Y. Search for Related Content PubMed PubMed Citation Articles by Moriki, T. Articles by Ikeda, Y. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 90 No. 2 (July 15), 1997: pp. 698-705 Expression and Functional Characterization of an Abnormal Platelet Membrane Glycoprotein Ib (Met239 Val) Reported in Patients With Platelet-Type von Willebrand Disease By Takanori Moriki, Mitsuru Murata, Tetsuya Kitaguchi, Hironobu Anbo, Makoto Handa, Kiyoaki Watanabe, Hoyu Takahashi, and Yasuo Ikeda From the Departments of Internal Medicine, Blood Center, and Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan; and the Blood Transfusion Division, Niigata University School of Medicine, Niigata, Japan.     ABSTRACT Abstract Introduction Methods Results Discussion References Platelet-type von Willebrand disease (vWD) is a congenital bleeding disorder characterized by heightened ristocetin-induced platelet aggregation caused by abnormally high affinity between the platelet membrane glycoprotein (GP) Ib/IX complex and von Willebrand factor (vWF ). Two distinct point mutations, Gly233 to Val and Met239 to Val, have been reported in GPIb. We have constructed a recombinant GPIb fragment containing the latter mutation, Met239 to Val (M239V) and characterized the mutant molecule using two methods, ie, interaction between soluble vWF and immobilized M239V and inhibition of platelet aggregation by purified soluble M239V. Spontaneous binding (ie, binding without any inducers) was observed between 125I-vWF and immobilized M239V but not between 125I-vWF and immobilized wild-type (WT) GPIb. The addition of low concentrations of ristocetin (0.2 mg/mL) induced specific 125I-vWF binding to immobilized M239V, but not to WT GPIb. At high concentrations of ristocetin (1.2 mg/mL), both WT GPIb and M239V specifically bound to 125I-vWF. Thus, M239V reproduced the unique functional abnormality of the GPIb/IX complex in platelet-type vWD. Moreover, the purified soluble M239V inhibited platelet aggregation induced by low concentration of ristocetin (0.3 mg/mL) in platelet-rich plasma from a patient having Met239 to Val mutation, whereas purified WT did not. These results provide direct evidences that the reported point mutation is the responsible molecular basis of this disorder.     INTRODUCTION Abstract Introduction Methods Results Discussion References PLATELET-TYPE (or pseudo-) von Willebrand disease (vWD) is a congenital bleeding disorder with unique characteristics. In addition to the decreased levels of plasma von Willebrand factor (vWF ) common to several subtypes of vWD, heightened ristocetin-induced platelet aggregation is noteworthy. Aberrant interaction between the glycoprotein (GP) Ib/IX complex on the platelet surface and its ligand, vWF, in plasma is thought to initiate the activation of platelets that leads to intravascular platelet clumping, followed by consumption of platelets and vWF. An intrinsic defect in the GPIb/IX complex has been postulated that causes a hypersensitive interaction between the receptor and the ligand. A similar subtype of vWD designated as type 2B has been described, but the hypersensitivity was attributed to the abnormal function of the vWF molecule. GPIb/IX complex is a hetero-oligomeric platelet membrane receptor that consists of three subunits, GPIb (140 kD), GPIb (24 kD), and GPIX (17 kD).1-5 vWF binding domain on GPIb/IX complex has been analyzed in detail and determined to be located on the N-terminal 45-kD domain of GPIb.6-8 Studies using synthetic peptides have shown that the amino acid sequences from 251 to 279 and 235 to 262 in 45-kD domain are thought to be an important site in vWF binding.9,10 Four distinct families of platelet-type vWD have been reported in three different races.11-15 Recent molecular analyses have shown two distinct point mutations in GPIb among these families. The first one is a Gly233 to Val substitution in a Caucasian family16 and the second one is a Met239 to Val substitution in three families, one of Puerto Rican ancestry17 and two of Japanese ancestry.18 However, GPIb is only one component of the GPIb/IX complex on the platelet surface and whether other components such as GPIb, GPIX, or another part of GPIb participate in the abnormal function of this complex is still unclear. To show that the Met239 to Val mutation is the direct cause of platelet-type vWD, we introduced the molecular abnormality into a mammalian expression system, expressed a recombinant GPIb fragment containing the mutation, and described the unique binding characteristics of the mutant molecule for soluble vWF.     MATERIALS AND METHODS Abstract Introduction Methods Results Discussion References Construction of expression vectors and site-directed mutagenesis. A recombinant expression plasmid was synthesized to contain cDNA encoding a partial GPIb sequence (His1-Ala302 ) corresponding to the N-terminal 45-kD extracytoplasmic domain that includes the vWF binding site.6-10 The plasmid has a neomycin cassette for selection. A recombinant plasmid encoding mutant GPIb, Met239 to Val, was synthesized by site-directed mutagenesis, as described.8,19,20 The DNA sequence was verified by sequence analysis and it was confirmed that the introduced mutation was restricted to residue 239. Transfection, cell culture, and collection of conditioned medium. Transfection and cell culture were performed essentially as described.8,19 Briefly, the two recombinant plasmids, encoding normal and mutant GPIb, were independently transfected into CHO-K1 cells by the calcium phosphate procedure.21 Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 0.5 mmol/L nonessential amino acid solution, 10% heat-inactivated fetal calf serum (GIBCO, Grand Island, NY) and 800 µg/mL of geneticin (Sigma, St Louis, MO) to select stable transfectants. After the establishment of cell lines, culture supernatants were collected and assayed for GPIb antigen. Transfected cells were grown to 80% confluence in serum-containing medium, washed with serum-free medium, and incubated in serum-free medium for 24 hours. The supernatant containing the recombinant protein was collected. Serum-free culture medium of nontransfected (NT) CHO-K1 cells was simultaneously collected as a control. Quantitation and immunologic evaluation of the recombinant GPIb fragments by anti-GPIb antibodies. Recombinant GPIb fragments with normal (wild-type [WT]) or mutant (M239V) sequence secreted in culture medium from CHO cells were quantitated based on immunologic reactivity with mouse anti-GPIb monoclonal antibody (MoAb) LJ-Ib1 (generous gift of Dr Z.M. Ruggeri, La Jolla, CA), which recognizes a epitope within the first 237 residues of GPIb and reacts better under reducing condition.6,7 Serum-free culture media containing the recombinant fragments were serially diluted, reduced by treatment with 30 mmol/L dithiothreitol at 37°C for 1 hour, and immobilized onto a nitrocellulose membrane (0.45-µm pore size; Bio-Rad, Hercules, CA) using an enzyme-linked immunofiltration assay (ELIFA) apparatus (Pierce Chemical Co, Rockford, IL) with a peristaltic pump. The membrane was soaked in Blotto (50 mg/mL fat-free dry milk, 0.25 mmol/L phenylmethylsulfonyl fluoride, 0.15 mol/L NaCl in phosphate buffer, pH 7.3) for 2 hours at 22°C to 25°C with constant shaking and incubated with LJ-Ib1 (5 to 10 mg/mL) for 2 hours at 22°C to 25°C. After washing three times with Blotto, the membrane was transferred into a solution of 125I-labeled rabbit antimouse IgG for 2 hours at 22°C to 25°C, washed again three times with Blotto, and exposed to Kodak AR film (Eastman Kodak, Rochester, NY). Spots on the membrane corresponding to each medium sample were cut out and evaluated for radioactivity by -scintillation spectrometry. A standard semiquantitative curve was drawn and media containing WT or M239V were appropriately diluted with nontransfected CHO cell culture medium to ensure application of equivalent antigen amounts on the nitrocellulose membrane. View larger version (55K): [in this window] [in a new window]   Fig 1. Dot-blot analysis of the recombinant GPIb fragments, WT and M239V. Immunologic reactivity of the two recombinant proteins was evaluated using a panel of anti-GPIb antibodies. To quantitate the amount of GPIb antigen for dot-blot analysis, serum-free CHO-cell culture media containing either WT or M239V were first serially diluted and the amount of GPIb-related antigen was assessed using anti-GPIb MoAb LJ-Ib1. LJ-Ib1 recognizes an epitope within the first 237 residues in the N-terminal domain on GPIb and reacts better under reducing condition. Culture media containing either WT or M239V were then appropriately diluted with nontransfected CHO-cell culture medium and the equivalent amount of antigen was applied onto the nitrocellulose membrane. After incubation with one of the first antibodies (LJ-Ib1, GUR83/35, or anti-GPIb271-285 ), nitrocellulose membranes were incubated with 125I-antimouse IgG and autoradiographed. GUR83/35 recognizes conformation-dependent epitope in the N-terminal division of GPIb, whereas anti-GPIb271-285 recognizes linear epitopes created by a polypeptide sequence of GPIb271-285. Note that WT and M239V presented similar immunochemical reactivities to each anti-GPIb antibody tested, regardless of the presence (R) or absence (NR) of 50 mmol/L dithiothreitol in the medium before spotting on nitrocellulose membranes. NR, not reducing; R, reducing. The recombinant fragments (WT and M239V) were evaluated by dot-blot analysis for immunologic reactivity with mouse anti-GPIb MoAb GUR83/35, and a rabbit anti-GPIb271-285 antiserum. GUR83/35 recognizes a conformation-specific epitope between residues 1 and 302 of GPIb and blocks the binding of vWF to platelets in the presence of ristocetin (Tokuhira et al, unpublished observation). Anti-GPIb271-285 (kindly provided by Dr Z.M. Ruggeri) was raised by immunization with a peptide containing the GPIb sequence, Gly271-Glu285.22 Isolation of the recombinant GPIb fragments. Recombinant GPIb fragments were purified by thrombin-affinity chromatography, as described.23 Purified human thrombin was reacted with Hitrap NHS-Activated Sepharose 4B (Pharmacia, Uppsala, Sweden) according to the standard procedure. The column was preincubated in 50 mmol/L Tris-HCl (pH 7.4) containing 100 mmol/L NaCl, incubated with protein contained medium, and washed with the same buffer. The bound proteins were then eluted with 50 mmol/L Tris-HCl (pH 7.4) containing 500 mmol/L NaCl. 125I-vWF binding to the recombinant GPIb fragments. vWF was radiolabeled with 125I by the IODO-GEN (Pierce Chemical Co) procedure.24 WT and M239V GPIb fragments, either in culture media or in purified form, were evaluated for their ability to bind soluble vWF. For conditioned media, the amount of GPIb fragments was first quantitated by immunologic reactivity with LJ-Ib1 as described above. Media were then diluted with nontransfected culture medium to contain equal concentrations of GPIb antigen. For purified WT and M239V, the concentration was adjusted to 2 µg/mL. Recombinant GPIb fragments were immobilized onto nitrocellulose membranes by vacuum-drawing of 200 µL of culture medium using an ELIFA apparatus with a peristaltic pump. Protein binding sites were saturated by filtering 600 µL of HEPES/bovine serum albumin (BSA) buffer (20 mmol/L HEPES, 150 mmol/L NaCl, 1% BSA, pH 7.4) through the nitrocellulose membranes. Ristocetin or botrocetin was mixed with 125I-vWF and was incubated for 30 minutes. Fifty microliters of the mixture was then filtered through the nitrocellulose membrane with GPIb fragments immobilized on it for a period of 5 minutes. Membranes were washed with 200 µL of HEPES/BSA buffer, and the bound reactivity was determined. In some experiments, the inhibitory effect on the binding was evaluated by MoAbs to assess the specificity of the binding. NMC-4, an anti-vWF MoAb 25 (generous gift of Dr A. Yoshioka, Nara Medical University, Nara, Japan) and GUR83/35, an anti-GPIb MoAb, were used at final concentrations of 12 µg/mL and 15 µg/mL, respectively. Preparation of platelet-rich plasma (PRP) and platelet aggregation studies. Blood was drawn from a platelet-type vWD patient (propositus of family B, see Takahashi et al18 ) and mixed with 1:10 vol of 3.14% sodium citrate solution. PRP was prepared by centrifugation at 100g for 15 minutes. To estimate the inhibitory effects of the WT and M239V fragments against platelet aggregation, purified recombinant fragments were first incubated with PRP for 5 minutes. PRP was then added with ristocetin and was applied to platelet aggregometer (Nema Tracer T-638; Niko Bioscience, Inc, Tokyo, Japan). Statistical analyses. Analysis of variance (ANOVA) was used for the comparison of repeated measurements in multiple independent experiments. Either one-way or two-way layout ANOVA was used, as appropriate. The Bonferroni Post-Hoc test was applied to identify differences among the various groups in one experiment. For comparison of corresponding data between WT and M239V under various concentrations of ristocetin or botrocetin, two-way factorial ANOVA was performed with the use of the StatView (Abacus Concepts, Berkeley, CA) statistical software program on a Macintosh computer (Apple Computer Inc, Cupertino, CA). Scatchard-type analysis of the experimental data was performed using a computer-assisted program StatView. The dissociation constant (kd) and maximum binding (Bmax) were expressed as ranges of 95% confidence interval (95% CI). Analysis of covariance (ANCOVA) was used to test the difference in the two regression curves. A probability value (P value) of less than .05 was considered statistically significant.     RESULTS Abstract Introduction Methods Results Discussion References Immunologic analysis of the recombinant GPIb fragments (WT and M239V). Immunologic reactivity of equivalent amounts of recombinant GPIb fragments was assessed under reducing and nonreducing conditions using anti-GPIb antibodies (GUR83/35 and anti-GPIb271-285) in dot-blot analysis. Both WT and M239V showed similar immunologic reactivities with each antibody (Fig 1), suggesting that the mutant fragment is secreted similarly to the native molecule to the culture medium and is immunologically indistinguishable from native GPIb molecule. Binding of 125I-vWF to the recombinant GPIb fragments (WT and M239V) in the absence of inducers. Consistent with previous results, no significant binding between WT and 125I-vWF was detected in the absence of inducers such as ristocetin or botrocetin (Fig 2). On the other hand, M239V specifically bound to 125I-vWF in the absence of inducers, as shown by the complete inhibition of the binding by an anti-vWF MoAb, NMC-4, although the extent of binding was much less than that attainable with ristocetin stimulation. Statistical analyses of 10 independent experiments using two-way layout ANOVA showed that 125I-vWF binding to M239V was significantly higher than that to NT (P < .01), but 125I-vWF binding to WT was statistically not different from that to NT. The statistical results shown in Fig 2 were the consequence of Bonferroni Post-Hoc test on 1 experiment that was representative of the 10 experiments. View larger version (36K): [in this window] [in a new window]   Fig 2. Binding of 125I-vWF to WT or M239V in the absence of inducers. Nontransfected (NT) medium was used as a control (). Two hundred microliters of culture media from WT-transfected cells or M239V-transfected cells, containing equivalent amounts of GPIb antigen, was immobilized onto a nitrocellulose membrane. After blocking, 125I-vWF (0.15 µg/mL) was passed through the membranes and a bound radioactivity of each was assessed. Although no statistically significant 125I-vWF binding could be shown to WT (), specific spontaneous binding of 125I-vWF was observed to the mutant recombinant fragment M239V (; P < .01) and 125I-vWF, and this binding was inhibited by an anti-vWF MoAb, NMC-4 (). This conclusion was based on the statistical analyses of 10 independent experiments of the same kind by the use of two-way layout ANOVA. However, the statistical results shown in this figure were the consequence of Bonferroni Post-Hoc test on 1 experiment that is representative of the 10 independent experiments. This analysis showed that only the column indicated (*) was significantly (P < .01) higher than the remaining five columns. Also, comparisons of 125I-vWF binding to M239V in two different conditions [ie, NMC-4 (-) or (+)] showed that there was a statistically significant difference. However, no differences were demonstrated in the binding to NT [NMC-4 (-) or (+)] or to WT [NMC-4 (-) or (+)]. The results shown are the mean (±SD) of triplicate determinations. Binding of 125I-vWF to the recombinant GPIb fragments (WT and M239V) in the presence of inducers. Because the enhanced ristocetin-induced platelet aggregation induced by low concentrations of ristocetin is the phenotypic abnormality of platelet-type vWD, we compared the interaction between the recombinant GPIb fragments and constant concentration of 125I-vWF (0.15 µg/mL) under conditions of low (0.2 mg/mL) versus high (1.0 mg/mL) concentrations of ristocetin, using the ELIFA apparatus with immobilized recombinant fragments on nitrocellulose membrane as described in the Materials and Methods. At 0.2 mg/mL ristocetin, no specific 125I-vWF binding to WT was observed (P > .05), whereas specific binding to M239V was shown (P < .05) that could be inhibited by NMC-4 or GUR83/35 (Fig 3A, left panel). At 1.0 mg/mL ristocetin, specific 125I-vWF binding was observed in both WT (P < .05) and M239V (P < .05), but much more prominent in the latter (Fig 3A, right panel). In each case, NMC-4 and GUR83/35 inhibited 125I-vWF binding to WT or M239V. All statistical analyses were performed by one-way layout ANOVA that compared values with control antibody, NMC-4, and GUR83/35. View larger version (24K): [in this window] [in a new window]   Fig 3. Binding of 125I-vWF to WT or M239V in the presence of ristocetin. Using the same method as described in the legend to Fig 2, WT and M239V were assayed for binding to 125I-vWF (0.15 µg/mL) in the presence of ristocetin. (A) The inhibitory effect on the binding was evaluated by MoAbs to assess the specificity of the binding. NMC-4 (), an anti-vWF MoAb (generous gift of Dr A. Yoshioka); GUR83/35 (), an anti-GPIb MoAb; and an indifferent antibody () were used. (Left panel) At a low concentration of ristocetin (0.2 mg/mL), WT did not specifically bind to 125I-vWF (P < .05), whereas M239V did (P < .05). (Right panel) At a high concentration of ristocetin (1.0 mg/mL), WT bound to 125I-vWF and M239V binding to vWF was enhanced. Anti-vWF MoAb NMC-4 and anti-GPIb MoAb GUR83/35 inhibited 125I-vWF binding in all of the conditions shown. The statistical analyses were perfomed using one-way layout ANOVA, which showed that, at 0.2 mg/mL ristocetin, there were no statistically significant difference between the three conditions (control antibody, NMC-4, and GUR83/35) in 125I-vWF binding to NT or WT (P < .05), but there was a difference between the three conditions in the binding to M239V (P < .05). On the other hand, at 1.0 mg/mL ristocetin, there were significant differences between the three conditions in WT and M239V (P < .05), but not in NT (P < .05). (B) 125I-vWF binding was measured in the presence of various concentrations of ristocetin. Nontransfected (NT) medium was used as a control. At low ristocetin concentrations (0.2 to 0.6 mg/mL), the difference between WT and M239V in 125I-vWF binding was marked, whereas the difference was minimized at ristocetin concentrations greater than 1.0 mg/mL. Two-way factorial ANOVA showed significant interaction between the effect of ristocetin concentration and the two recombinant GPIb fragments (WT or M239V), ie, the two dose-response curves (WT and M239V) were statistically different (P < .05). The results shown are the mean (±SD) of triplicate determinations from one experiment that is representative of four. 125I-vWF (0.15 µg/mL) binding to the recombinant fragments increased with increasing ristocetin concentrations, but a binding plateau was reached at much lower concentrations in M239V (0.4 mg/mL) than in WT (1.2 mg/mL). The difference between WT and M239V in vWF binding was much more prominent at the ristocetin level between 0.2 mg/mL and 0.6 mg/mL (Fig 3B). Two-way factorial ANOVA showed significant interaction between the effect of ristocetin concentration and the two recombinant GPIb fragments (WT or M239V), ie, the two dose-dependent curves were statistically different (P < .05). Botrocetin reportedly gives rise to an active complex form with vWF.25 In the presence of various concentrations of botrocetin, no significant difference was observed between WT and M239V in their ability to bind 125I-vWF (0.15 µg/mL; Fig 4). Two-way factorial ANOVA showed no significant interaction between the effect of botrocetin concentration and the two recombinant GPIb fragments (WT or M239V; P > .05). View larger version (11K): [in this window] [in a new window]   Fig 4. Binding of 125I-vWF to WT or M239V in the presence of various concentrations of botrocetin. The experiment was essentially the same as that described in Fig 3, except that botrocetin was used to induce vWF-GPIb binding. Nontransfected (NT) medium was used as a control. There was no significant difference between WT and M239V in terms of botrocetin dose-dependent binding of 125I-vWF. Two-way factorial ANOVA showed no significant interaction between the effect of botrocetin concentration and the recombinant GPIb fragments (WT or M239V). Scatchard-type analysis of vWF binding to the purified recombinant GPIb fragments. Recombinant GPIb fragments were isolated by thrombin-affinity chromatography, and the purity of the protein was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by Coumassie blue staining. Saturation binding of 125I-vWF to WT or M239V was evaluated using the purified recombinant GPIb fragments. In the presence of 0.2 mg/mL ristocetin, scatchard-type analysis showed no saturable binding between 125I-vWF and WT, whereas specific binding was shown between 125I-vWF and M239V. On the other hand, at 1.2 mg/mL of ristocetin, both fragments showed saturable binding of vWF. Table 1 shows the calculated dissociation constant (kd) with 95% CI between purified GPIb fragments and 125I-vWF. At a ristocetin concentration of 0.2 mg/mL, no measurable affinity was shown between purified WT and 125I-vWF, whereas purified M239V and 125I-vWF gave a kd of 0.92 (0.29 ~ 1.55) × 10-8 mol/L. At a ristocetin concentration of 1.2 mg/mL, the calculated kds of WT and M239V were 1.21 × 10-8 mol/L (0.66 ~ 1.76 × 10-8 mol/L) and 0.60 × 10-8 mol/L (0.22 ~ 0.98 × 10-8 mol/L), respectively. These calculated kds were statistically equivalent as analyzed by ANCOVA (P < .05).   View this table: [in this window] [in a new window]   Table 1. Binding Parameters of Ristocetin-Induced vWF Interaction With Purified Recombinant GPIb Calculated From Scatchard-Type Analysis Effect of purified soluble recombinant GPIb fragments (WT and M239V) on platelet aggregation. Low concentration of ristocetin (0.3 mg/mL) induced platelet aggregation in PRP of the platelet-type vWD patient but not in PRP of normal control subject (data not shown). Preincubation of purified WT (200 µg/mL) in PRP did not interfere the aggregation of the patients' platelets. On the other hand, the same concentration of purified M239V completely inhibited the platelet aggregation (Fig 5). View larger version (15K): [in this window] [in a new window]   Fig 5. Effect of purified recombinant GPIb fragments on platelet aggregation of the platelet-type vWD patient induced by low concentration of ristocetin. PRP (1.4 × 105 platelets/mL) of the patient with Met239 Val substitution was mixed with purified recombinant GPIb (WT and M239V) at a final concentration of 200 µg/mL. After 3 minutes of incubation, ristocetin (0.3 mg/mL) was added to PRP. Aggregation of the patient's platelets was measured as the increase in light transmittance as a function of time. Platelet aggregation was completely inhibited by purified M239V, whereas it was not by purified WT in the same condition.     DISCUSSION Abstract Introduction Methods Results Discussion References The initial phase of hemostasis at the site of vascular injury begins with adhesion of platelets to the exposed subendothelium, leading to platelet activation and the formation of platelet thrombi. Among several receptors and ligands involved in the platelet-subendothelium interaction, the GPIb/IX complex on the platelet membrane and vWF in the subendothelium play a pivotal role in both normal hemostasis and pathological thrombosis. vWF is also present in plasma, but it does not bind to GPIb/IX complex under normal circumstances, because the interaction is believed to be strictly regulated to maintain normal blood flow conditions. It is assumed that conformational changes in either or both of the two molecules are necessary to initiate the interaction. In in vitro experiments, the interaction can be induced by several ways, including chemical agonists such as ristocetin, shear stress,26 and using asialo vWF in place of normal vWF.27 Platelet-type vWD and type 2B vWD are congenital bleeding disorders characterized by the hypersensitivity of the vWF-GPIb interaction. The consumption of vWF and/or platelets is believed to account for the bleeding diathesis in these disorders. The pathophysiology of the disease has been characteristically represented in in vitro experiments in two distinct ways: one using the aggregation inducer ristocetin and the other using a physical shear stress stimulus. Ristocetin-induced platelet aggregation is heightened in both of the bleeding disorders and, more importantly, low concentrations of ristocetin, which never cause aggregation in normal platelets, induce the aggregation of patients' platelets. vWF-dependent shear-induced platelet aggregation was observed under low shear stress (15 dyne/cm2 ) in both of the disorders, which never gives rise to platelet aggregation in normal individuals,28 for which more than 80 dyne/cm2 is necessary.29 In type 2B vWD, the qualitive abnormality of vWF is thought to explain the hypersensitivity of the interaction, and recent molecular analyses have shown several point mutations in the GPIb binding domain of vWF.30-32 In platelet-type vWD, two single point mutations in GPIb have been described. The first one is Gly233 to Val substitution,16 and the second, Met239 to Val, was reported in three distinct families, one from Puerto Rican ancestry17 and two from Japanese ancestry.18 An in vitro mammalian expression system has successfully represented the phenotypical abnormality of the Gly233 to Val substitution.33 In the present study, we have constructed a recombinant GPIb fragment that contains the second substitution, Met239 to Val (designated M239V), and intended to show the direct evidence that the mutation could cause the unique characteristics of the hypersensitive interaction of GPIb with a normal vWF molecule. The mutant fragment M239V bound to 125I-vWF in the absence of any inducers, whereas the wild-type fragment (WT) did not. Moreover, M239V bound to 125I-vWF at a lower concentration of ristocetin as compared with WT. These results are consistent with one of the clinical laboratory features of platelet-type vWD, ie, platelets of these patients aggregate in vitro in the presence of low concentrations of ristocetin that never induce aggregation of normal platelets. With respect to the spontaneous interaction of vWF and GPIb/IX, purified type 2B vWF in solution has been reported to bind to normal GPIb in the absence of any modulating substances.34 Moreover, normal vWF in solution directly interacts with platelets in platelet-type vWD and induces aggregation.35-37 In a mammalian expression system, Ware et al30 have shown that a recombinant vWF molecule containing a type 2B mutation (Trp550 Cys) binds to GPIb without ristocetin modulation. However, analysis of interaction between normal vWF and recombinant GPIb fragment containing Gly233 to Val mutation showed no spontaneous binding, although the low concentration of ristocetin (0.34 mg/mL) supported specific binding between the two molecules.33 In the present study, we used the same assay system as in the previous analysis,33 but clearly detected spontaneous binding between normal vWF and GPIb (Met239 Val). The discrepancy in the two results is currently unexplained, but may reflect subtle conformational differences between the two molecules (Gly233 Val and Met239 Val) that determine the difference in the sensitivity to soluble vWF in our assay. However, it is still unclear whether the spontaneous binding is of pathophysiological relevance in patients with platelet-type vWD, because binding of vWF to affected GPIb would rather be attributable to or affected by other factors such as shear stress. Unlike the results using ristocetin, no significant difference between WT and M239V was observed with respect to the botrocetin concentration necessary to induce the binding. The differences observed in the two inducers reflect the distinct mechanisms by which they induce aggregation. Ristocetin presumably acts as a dimer and mediates the binding interaction of vWF and GPIb by bridging both molecules,38 whereas botrocetin affects only vWF, forming an active complex with vWF that can bind to the GPIb/IX complex regardless of whether the receptor is upregulated.39 Scatchard-type analysis for the affinity between the recombinant fragments and vWF showed several interesting characteristics of the binding interaction (Table 1). At low ristocetin concentrations (0.2 mg/mL), no binding affinity between vWF and WT could be detected, whereas dissociation constant was calculated for M239V binding. At high ristocetin concentrations (1.2 mg/mL), both WT and M239V showed statistically equivalent dissociation constants for 125I-vWF, the values of which are very comparable to that of WT reported in a previous study.8 It is surprising that 125I-vWF bound to recombinant GPIb with statistically equivalent affinity under different conditions, ie, to M239V at low or high ristocetin concentrations and to WT at high ristocetin concentrations. These findings suggest that the enhanced binding of M239V is not due to a change in the vWF binding site itself, but rather to a change in the modulatory site on GPIb that upregulates the receptor function. Recent analyses of the vWF binding site identified amino acid residues 251 to 279 and 235 to 262 in the 45-kD domain of the GPIb sequence as important sites for the interaction.9,10 Moreover, an epitope analysis of an MoAb raised against platelet-type vWD platelets with the other mutation, Gly233 Val, showed the regulatory effects of this region on vWF-dependent platelet aggregation.40 Therefore, the substitutions of Val for Met at residue 239 and Val for Gly at residue 233 described in platelet-type vWD might determine a change in the modulatory sites, leading to a persistently active vWF binding site. In other words, the amino acid region around residues 233 to 239 might work as an on and off switch effector that regulates the status of the vWF binding site. The inhibitory effect of the purified M239V but not of WT on platelet aggregation of platelet-type vWD induced by low concentrations of ristocetin further confirms that the characteristic phenotype of the disorder is caused by Met239 Val substitution of GPIb. In conclusion, our results using a mammalian expression system clearly established a molecular basis of platelet-type vWD. The phenotype of the Met239 to Val substitution reported in two Japanese families and a family of Puerto Rican ancestry was represented in our in vitro functional assays; ie, binding of soluble vWF to the mutant GPIb fragment was induced by low ristocetin concentrations or even in its absence. Moreover, the mutant recombinant GPIb fragment may be a model for the active form of GPIb, a molecule that plays a key role in regulating the initial steps of platelet activation. Such a model might provide important information in approaches to preventing thrombosis and will show a new aspect of antiplatelet therapy.     FOOTNOTES    Submitted July 23, 1996; accepted March 4, 1997.    Supported in part by a Grant-in-Aid for Scientific Research No. 05670930 (to M.M.) from the Ministry of Education, Science and Culture of Japan.    Address reprint requests to Mitsuru Murata, MD, Division of Hematology, Department of Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160, Japan.    The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hearly marked ``advertisment'' in accordance with 18 U.S.C. section 1734 solely to indicate this fact.     ACKNOWLEDGMENT The authors thank Dr Z.M. Ruggeri and Dr A. Yoshioka for providing antibodies to GPIb and vWF. The expert editorial assistance of Marina Hoffman is gratefully appreciated.     REFERENCES Abstract Introduction Methods Results Discussion References 1. Lopez JA, Chung DW, Fujikawa K, Hagen FS, Papayannopoulou T, Roth GJ: Cloning of the chain of human platelet glycoprotein Ib: A transmembrane protein with homology to leucine rich 2-glycoprotein. Proc Natl Acad Sci USA 84:5615, 1987[Abstract/Free Full Text] 2. Lopez JA, Chung DW, Fujikawa K, Hagen FS, Davie EW, Roth GJ: The and chain of human platelet glycoprotein Ib are both transmembrane proteins containing a leucine-rich amino acid sequence. Proc Natl Acad Sci USA 85:2135, 1988[Abstract/Free Full Text] 3. Hickey MJ, Williams SA, Roth G: Human platelet glycoprotein IX: An adhesive prototype of leucine-rich glycoproteins with flank-center-flank structures. Proc Natl Acad Sci USA 86:6773, 1989[Abstract/Free Full Text] 4. Modderman PW, Admiraal LG, Sonnenberg A, von dem Borne AEGKr: Glycoproteins V and Ib-IX form a noncovalent complex in the platelet membrane. J Biol Chem 267:364, 1992[Abstract/Free Full Text] 5. Lanza F, Morales M, de La Salle C, Cazenave JP, Clemetson KJ, Shimomura T, Phillips DR: Cloning and characterization of the gene encoding the human platelet glycoprotein V. J Biol Chem 268:20801, 1993[Abstract/Free Full Text] 6. Handa M, Titani K, Holland LZ, Roberts JR, Ruggeri ZM: The von Willebrand factor-binding domain of platelet membrane glycoprotein Ib. Characterization by monoclonal antibodies and partial amino acid sequence analysis of proteolytic fragments. J Biol Chem 261:12579, 1986[Abstract/Free Full Text] 7. Vicente V, Kostel PJ, Ruggeri ZM: Isolation and functional characterization of the von Willebrand factor-binding domain located between residues His(1)-Arg(293) of the alpha-chain of glycoprotein Ib. J Biol Chem 263:18473, 1988[Abstract/Free Full Text] 8. Murata M, Ware J, Ruggeri ZM: Site-directed mutagenesis of a soluble recombinant fragment of platelet glycoprotein Ib demonstrating negatively charged residues involved in von Willebrand factor binding. J Biol Chem 266:15474, 1991[Abstract/Free Full Text] 9. Katagiri Y, Hayashi Y, Yamamoto K, Tanoue K, Kosaki G, Yamazaki H: Localization of von Willebrand factor and thrombin-interactive domains on human platelet glycoprotein Ib. Thromb Haemost 63:122, 1990[Medline] [Order article via Infotrieve] 10. Vicente V, Houghten RA, Ruggeri ZM: Identification of a site in the alpha chain of platelet glycoprotein Ib that participates in von Willebrand factor binding. J Biol Chem 265:274, 1990[Abstract/Free Full Text] 11. Weiss HJ, Meyer D, Rabinowitz R, Pietu G, Girma JP, Vicic WJ, Rogers J: Pseudo-von Willebrand disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med 306:326, 1982[Abstract] 12. Takahashi H: Studies on the pathophysiology and treatment of von Willebrand's disease. IV. Mechanism of increased ristocetin-induced platelet aggregation in von Willebrand's disease. Thromb Res 19:857, 1980[Medline] [Order article via Infotrieve] 13. Takahashi H: Studies on the pathophysiology and treatment of von Willebrand's disease. I. Spectrum of von Willebrand's disease in Niigata. Acta Haematol Jpn 44:154, 1981 14. Takahashi H, Nagayama R, Hattori A, Ihzumi T, Tsukada T, Shibata A: von Willebrand disease associated with familial thrombocytopenia and increased ristocetin-induced platelet aggregation. Am J Hematol 10:89, 1981[Medline] [Order article via Infotrieve] 15. Miller JL, Castella A: Platelet-type von Willebrand's disease: Characterization of a new bleeding disorder. Blood 60:790, 1982[Abstract/Free Full Text] 16. Miller JL, Cunningham D, Lyle VA, Finch CN: Mutation in the gene encoding the achain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci USA 88:4761, 1991[Abstract/Free Full Text] 17. Russell SD, Roth GJ: Pseudo-von Willebrand disease: A mutation in the platelet glycoprotein Ib gene associated with a hyperactive surface receptor. Blood 81:1787, 1993[Abstract/Free Full Text] 18. Takahashi H, Murata M, Moriki T, Anbo H, Furukawa T, Nikkuni K, Shibata A, Handa M, Kawai Y, Watanabe K, Ikeda Y: Substitution of Val for Met at residue 239 of platelet glycoprotein Ib in Japanese patients with platelet-type von Willebrand disease. Blood 85:727, 1995[Abstract/Free Full Text] 19. Marchese P, Murata M, Mazzucato M, Pradella P, De Marco L, Ware J, Ruggeri ZM: Identification of three tyrosine residues of glycoprotein Ib with distinct roles in von Willebrand factor and -thrombin binding. J Biol Chem 270:9571, 1995[Abstract/Free Full Text] 20. Kunkel TA, Roberts JD, Zakour RA: Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol 154:367, 1987[Medline] [Order article via Infotrieve] 21. Chen C, Okayama H: High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7:2745, 1987[Abstract/Free Full Text] 22. Murata M, Furihata K, Ishida F, Russel SR, Ware J, Ruggeri ZM: Genetic and structural characterization of an amino acid dimorphism in glycoprotein Ib involved in platelet transfusion refractoriness. Blood 79:3086, 1992[Abstract/Free Full Text] 23. Wicki AN, Clemetson JM, Steiner B, Schnippering W, Clemetson KJ: Isolation and characterization of glycoprotein Ib. Methods Enzymol 215:276, 1992[Medline] [Order article via Infotrieve] 24. Fraker PJ, Speck JC: Protein and cell membrane iodinations with sparingly soluble chloride, 1,3,4,6-tetracloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun 80:849, 1978[Medline] [Order article via Infotrieve] 25. Fujimura Y, Holland LZ, Ruggeri ZM, Zimmerman TS: The von Willebrand factor domain-mediated botrocetin-induced binding to glycoprotein Ib lies between Val449 and Lys728. Blood 70:985, 1986[Abstract/Free Full Text] 26. Weiss HJ, Turitto VT, Baumgartner HR: Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate-dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome. J Lab Clin Med 92:750, 1978[Medline] [Order article via Infotrieve] 27. Miller JL, Ruggeri ZM, Lyle VA: Unique interactions of asialo von Willebrand factor with platelets in platelet-type von Willebrand disease. Blood 70:1804, 1987[Abstract/Free Full Text] 28. Murata M, Fukuyama M, Sato K, Fujimura Y, Yoshioka A, Takahashi H, Handa M, Kawai Y, Watanabe K, Ikeda Y: Low shear stress can initiate von Willebrand factor-dependent platelet aggregation in patients with type IIB and platelet-type von Willebrand disease. J Clin Invest 92:1555, 1993 29. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM: The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 87:1234, 1991 30. Ware J, Dent J, Azuma H, Sugimoto M, Kyrle PA, Yoshioka A, Ruggeri ZM: Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor. Proc Natl Acad Sci USA 88:2946, 1991[Abstract/Free Full Text] 31. Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE: Molecular basis of von Willebrand disease type IIB. J Clin Invest 87:1220, 1991 32. Cooney KA, Nichols WC, Bruck ME, Bahou WF, Shapiro AD, Bowie EJV, Gralnick HR, Ginsburg D: The molecular defect in type 2B von Willebrand disease. J Clin Invest 87:1227, 1991 33. Murata M, Russell SR, Ruggeri ZM, Ware J: Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib fragment. J Clin Invest 91:2133, 1993 34. De Marco L, Mazzucato M, De Roia D, Casonato A, Federici AB, Girolami A, Ruggeri ZM: Distinct abnormalities in the interaction of purified type IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib and IIb-IIIa. J Clin Invest 86:785, 1990 35. Miller JL, Kupinski JM, Castella A, Ruggeri ZM: von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. J Clin Invest 72:1532, 1983 36. Takahashi H, Handa M, Watanabe K, Ando Y, Nagayama R, Hattori A, Shibata A, Federici AB, Ruggeri ZM, Zimmerman TS: Further characterization of platelet-type von Willebrand's disease in Japan. Blood 64:1254, 1984[Abstract/Free Full Text] 37. Takahashi H, Shibata A: Agglutination of formalin-fixed, platelet-type von Willebrand's disease platelets by human von Willebrand factor. Thromb Haemost 52:267, 1984[Medline] [Order article via Infotrieve] 38. Scott JP, Montgomery RR, Retzinger GS: Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem 233:8149, 1991 39. Andrews RK, Booth WJ, Gorman JJ, Castaldi PA, Berndt MC: Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex. Biochemistry 28:8317, 1989[Medline] [Order article via Infotrieve] 40. Miller JL, Lyle VA: Mimotope/anti-mimotope probing of structural relationships in platelet glycoprotein Ib. Proc Natl Acad Sci USA 93:3565, 1996[Abstract/Free Full Text] © 1997 by The American Society of Hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Lou and C. Zhu Flow induces loop-to-{beta}-hairpin transition on the {beta}-switch of platelet glycoprotein Ib{alpha} PNAS, September 16, 2008; 105(37): 13847 - 13852. [Abstract] [Full Text] [PDF] L. J. Suva, E. Hartman, J. D. Dilley, S. Russell, N. S. Akel, R. A. Skinner, W. R. Hogue, U. Budde, K. I. Varughese, T. Kanaji, et al. Platelet Dysfunction and a High Bone Mass Phenotype in a Murine Model of Platelet-Type von Willebrand Disease Am. J. Pathol., February 1, 2008; 172(2): 430 - 439. [Abstract] [Full Text] [PDF] M. Othman, C. Notley, F. L. Lavender, H. White, C. D. Byrne, D. Lillicrap, and D. F. O'Shaughnessy Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease Blood, June 1, 2005; 105(11): 4330 - 4336. [Abstract] [Full Text] [PDF] R. I. Handin Inherited Platelet Disorders Hematology, January 1, 2005; 2005(1): 396 - 402. [Abstract] [Full Text] [PDF] J. J. Dumas, R. Kumar, T. McDonagh, F. Sullivan, M. L. Stahl, W. S. Somers, and L. Mosyak Crystal Structure of the Wild-type von Willebrand Factor A1-Glycoprotein Ib{alpha} Complex Reveals Conformation Differences with a Complex Bearing von Willebrand Disease Mutations J. Biol. Chem., May 28, 2004; 279(22): 23327 - 23334. [Abstract] [Full Text] [PDF] A. S. Tait, S. L. Cranmer, S. P. Jackson, I. W. Dawes, and B. H. Chong Phenotype changes resulting in high-affinity binding of von Willebrand factor to recombinant glycoprotein Ib-IX: analysis of the platelet-type von Willebrand disease mutations Blood, September 15, 2001; 98(6): 1812 - 1818. [Abstract] [Full Text] [PDF] T. Katayama, Y. Ikeda, M. Handa, T. Tamatani, S. Sakamoto, M. Ito, Y. Ishimura, and M. Suematsu Immunoneutralization of Glycoprotein Ib{alpha} Attenuates Endotoxin-Induced Interactions of Platelets and Leukocytes With Rat Venular Endothelium In Vivo Circ. Res., May 26, 2000; 86(10): 1031 - 1037. [Abstract] [Full Text] [PDF] J.-f. Dong, A. J. Schade, G. M. Romo, R. K. Andrews, S. Gao, L. V. McIntire, and J. A. Lopez Novel Gain-of-function Mutations of Platelet Glycoprotein Ibalpha by Valine Mutagenesis in the Cys209-Cys248 Disulfide Loop. FUNCTIONAL ANALYSIS UNDER STATIC AND DYNAMIC CONDITIONS J. Biol. Chem., September 1, 2000; 275(36): 27663 - 27670. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Moriki, T. Articles by Ikeda, Y. Search for Related Content PubMed PubMed Citation Articles by Moriki, T. Articles by Ikeda, Y. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?

	Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020